How Should We Activate Ferrate(VI)? Fe(IV) and Fe(V) Tell Different Stories about Fluoroquinolone Transformation and Toxicity Changes
Environmental Science & Technology · 12.03.2024 · 58 (10) · 4812-4823
DOI: 10.1021/acs.est.3c10800 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Science & Technology, online erschienen am 01.03.2024. Verfasst von Zhongjuan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Hydraulics and Mountain River Engineering, College of Architecture and Environment, Sichuan University, Chengdu 610065, China. Hauptthemen laut MEDLINE: Water Pollutants, Chemical, Environmental Pollutants, Water Purification. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Natural Science Foundation of Sichuan Province, National Natural Science Foundation of China, Sichuan Province scientific and technological achievements transfer and transformation demonstration project.
Abstract (Originalsprache)
Many studies have investigated activation of ferrate (Fe(VI)) to produce reactive high-valent iron intermediates to enhance the oxidation of micropollutants. However, the differences in the risk of pollutant transformation caused by Fe(IV) and Fe(V) have not been taken seriously. In this study, Fe(VI)-alone, Fe3+/Fe(VI), and NaHCO3/Fe(VI) processes were used to oxidize fluoroquinolone antibiotics to explore the different effects of Fe(IV) and Fe(V) on product accumulation and toxicity changes. The contribution of Fe(IV) to levofloxacin degradation was 99.9% in the Fe3+/Fe(VI) process, and that of Fe(V) was 89.4% in the NaHCO3/Fe(VI) process. The cytotoxicity equivalents of levofloxacin decreased by 1.9 mg phenol/L in the Fe(IV)-dominant process while they significantly (p < 0.05) increased by 4.7 mg phenol/L in the Fe(V)-dominant process. The acute toxicity toward luminescent bacteria and the results for other fluoroquinolone antibiotics also showed that Fe(IV) reduced the toxicity and Fe(V) increased the toxicity. Density functional theory calculations showed that Fe(V) induced quinolone ring opening, which would increase the toxicity. Fe(IV) tended to oxidize the piperazine group, which reduced the toxicity. These results show the different-pollutant transformation caused by Fe(IV) and Fe(V). In future, the different risk outcomes during Fe(VI) activation should be taken seriously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Hydraulics and Mountain River Engineering, College of Architecture and Environment, Sichuan University, Chengdu 610065, China.
- Sino-German Centre for Water and Health Research, Sichuan University, Chengdu 610065, China.
ORCID-Profile: Ye Du, Chuan-Shu He, ZhaoKun Xiong, Bo Lai
Förderung
- Natural Science Foundation of Sichuan Province
- National Natural Science Foundation of China
- Sichuan Province scientific and technological achievements transfer and transformation demonstration project
Zitieren
APA
Wang, Z., Du, Y., Liu, T., Li, J., He, C. S., Liu, Y., Xiong, Z., & Lai, B. (2024). How Should We Activate Ferrate(VI)? Fe(IV) and Fe(V) Tell Different Stories about Fluoroquinolone Transformation and Toxicity Changes. Environmental Science & Technology, 58(10), 4812-4823. https://doi.org/10.1021/acs.est.3c10800
Vancouver
Wang Z, Du Y, Liu T, Li J, He CS, Liu Y, et al. How Should We Activate Ferrate(VI)? Fe(IV) and Fe(V) Tell Different Stories about Fluoroquinolone Transformation and Toxicity Changes. Environmental Science & Technology. 2024;58(10):4812-4823. doi:10.1021/acs.est.3c10800
BibTeX
@article{Wang2024,
author = {Wang, Zhongjuan and Du, Ye and Liu, Tong and Li, Jie and He, Chuan-Shu and Liu, Yang and Xiong, ZhaoKun and Lai, Bo},
title = {How Should We Activate Ferrate(VI)? Fe(IV) and Fe(V) Tell Different Stories about Fluoroquinolone Transformation and Toxicity Changes},
journal = {Environmental Science & Technology},
year = {2024},
volume = {58},
number = {10},
pages = {4812--4823},
doi = {10.1021/acs.est.3c10800}
}
EUVIMED